LungLife AI, INC Confirmation of AGM (9518X)
02 Maggio 2023 - 8:00AM
UK Regulatory
TIDMLLAI
RNS Number : 9518X
LungLife AI, INC
02 May 2023
LungLife AI, Inc.
(the "Company" or "LungLife")
Confirmation of AGM
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, confirms that its Annual General Meeting
("AGM") will be held at 3:00 P.M. (BST) on Thursday 4 May 2023, at
Investec Bank plc, 30 Gresham Street, London, EC2V 7QP.
For those shareholders who would like to dial into the meeting,
please register by emailing LungLifeAI@walbrookpr.com or calling
+44 (0)20 7933 8780 and the dial in link will be sent by email.
The Notice of AGM, Form of Direction and associated Form of
Proxy are available on the Company's website and have already been
posted to those shareholders who have opted out of electronic
communications . The resolutions to be proposed at the AGM are
summarised in the Notice of AGM. All documents are available here:
https://investors.lunglifeai.com/
The results of voting on the resolutions will be announced via a
regulatory information service and posted on the Company's website
as soon as practicable after the AGM.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& J oint Broker)
Virginia Bull / Cameron MacRitchie
/ Lydia Zychowska
Goodbody (Joint Broker) Tel: +44 (0) 20 3841 6202 / +353 (1)
Tom Nicholson / Stephen Kane 667 0420
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Stephanie Cuthbert / Alice Woodings Mob: 07980 541 893 / 07407 804 654 /
/ Phillip Marriage 07867 984 082
About LungLife
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to
lung cancer. Our Vision is to invert the 20:80 ratio such that in
years to come at least 80% of lung cancer is detected early.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOABLGDSIBDDGXI
(END) Dow Jones Newswires
May 02, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Lunglife Ai (LSE:LLAI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Lunglife Ai (LSE:LLAI)
Storico
Da Giu 2023 a Giu 2024